Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China.
<h4>Background</h4>Sunitinib was approved several years ago as a first-line drug for treating metastatic renal cell carcinoma (mRCC); however, its high price and broad side effects when administered at the standard dose have limited its clinical use. A clinical trial (NCT02072031) confir...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0281402 |
| _version_ | 1811167182704345088 |
|---|---|
| author | Jingyang Lin Qingxia Fang Xiaochun Zheng |
| author_facet | Jingyang Lin Qingxia Fang Xiaochun Zheng |
| author_sort | Jingyang Lin |
| collection | DOAJ |
| description | <h4>Background</h4>Sunitinib was approved several years ago as a first-line drug for treating metastatic renal cell carcinoma (mRCC); however, its high price and broad side effects when administered at the standard dose have limited its clinical use. A clinical trial (NCT02072031) confirmed that anlotinib could be used as the first-line treatment for mRCC. This study was conducted to evaluate the cost-effectiveness of anlotinib as a first-line treatment for mRCC compared to that of sunitinib in China.<h4>Methods</h4>A Markov model was established to compare the cost-effectiveness of anlotinib with that of sunitinib. Clinical data were obtained from a multi-center phase II trial (clinical trial information: NCT02072031). Utility values were obtained from the literature. Total costs were calculated from a Chinese societal perspective. A sensitivity analysis was conducted to assess the model uncertainty. The life-year (LY), quality-adjusted life-year (QALY), and incremental cost-effectiveness ratio were calculated.<h4>Results</h4>The base-case analysis over a lifetime horizon of 10 years showed that the anlotinib group had 2.196 LYs and 1.487 QALYs at a total cost of $68,597.84. The sunitinib group had 2.194 LYs and 1.432 QALYs at a total cost of $88,060.02. This resulted in incremental cost-effectiveness ratios (ICER) of anlotinib versus sunitinib of $-9,210,858.93 per LYs and $-354,117.07 per QALYs, suggesting that anlotinib is a more effective and less costly strategy than sunitinib.<h4>Conclusion</h4>Anlotinib may be a more cost-effective first-line treatment strategy for mRCC than sunitinib in China. |
| first_indexed | 2024-04-10T16:06:01Z |
| format | Article |
| id | doaj.art-776aa9cac81d488e81e0fce4dc9621ee |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-10T16:06:01Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-776aa9cac81d488e81e0fce4dc9621ee2023-02-10T05:31:43ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01182e028140210.1371/journal.pone.0281402Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China.Jingyang LinQingxia FangXiaochun Zheng<h4>Background</h4>Sunitinib was approved several years ago as a first-line drug for treating metastatic renal cell carcinoma (mRCC); however, its high price and broad side effects when administered at the standard dose have limited its clinical use. A clinical trial (NCT02072031) confirmed that anlotinib could be used as the first-line treatment for mRCC. This study was conducted to evaluate the cost-effectiveness of anlotinib as a first-line treatment for mRCC compared to that of sunitinib in China.<h4>Methods</h4>A Markov model was established to compare the cost-effectiveness of anlotinib with that of sunitinib. Clinical data were obtained from a multi-center phase II trial (clinical trial information: NCT02072031). Utility values were obtained from the literature. Total costs were calculated from a Chinese societal perspective. A sensitivity analysis was conducted to assess the model uncertainty. The life-year (LY), quality-adjusted life-year (QALY), and incremental cost-effectiveness ratio were calculated.<h4>Results</h4>The base-case analysis over a lifetime horizon of 10 years showed that the anlotinib group had 2.196 LYs and 1.487 QALYs at a total cost of $68,597.84. The sunitinib group had 2.194 LYs and 1.432 QALYs at a total cost of $88,060.02. This resulted in incremental cost-effectiveness ratios (ICER) of anlotinib versus sunitinib of $-9,210,858.93 per LYs and $-354,117.07 per QALYs, suggesting that anlotinib is a more effective and less costly strategy than sunitinib.<h4>Conclusion</h4>Anlotinib may be a more cost-effective first-line treatment strategy for mRCC than sunitinib in China.https://doi.org/10.1371/journal.pone.0281402 |
| spellingShingle | Jingyang Lin Qingxia Fang Xiaochun Zheng Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China. PLoS ONE |
| title | Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China. |
| title_full | Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China. |
| title_fullStr | Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China. |
| title_full_unstemmed | Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China. |
| title_short | Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China. |
| title_sort | cost effectiveness analysis of anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma in china |
| url | https://doi.org/10.1371/journal.pone.0281402 |
| work_keys_str_mv | AT jingyanglin costeffectivenessanalysisofanlotinibversussunitinibasfirstlinetreatmentformetastaticrenalcellcarcinomainchina AT qingxiafang costeffectivenessanalysisofanlotinibversussunitinibasfirstlinetreatmentformetastaticrenalcellcarcinomainchina AT xiaochunzheng costeffectivenessanalysisofanlotinibversussunitinibasfirstlinetreatmentformetastaticrenalcellcarcinomainchina |